banter and General Discussion, page-11092

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more powerful than existing treatments. Because of this, the immunology and inflammation (I&I) therapeutic area has recently been attracting a major wave of investment within the biopharma industry and is expected to grow significantly in the coming years.

According to Wellington Management, there have been three “waves” of I&I drugs in recent years. The first wave came about with the use of steroids and chemotherapy, which were frequently found to be worse than the underlying disease they were intended to treat.

Then, in the early 2000s, biomedical advancements in the basic science of immunology combined with productizing therapeutic antibodies enabled the second wave. Here, doctors could finally direct an antibody at a defined immune target, allowing them to control chronic autoinflammatory diseases such as multiple sclerosis and rheumatoid arthritis without indiscriminate immunosuppression. Simultaneously, new therapeutic antibodies were able to target previously undruggable pathways.

And, finally, the third wave of drugs is happening today, with novel targets and improved modalities. This third wave of potential drugs is what currently makes the I&I therapeutic area market so exciting to investors. In this article, we explore some of the latest I&I deals, as well as why the market is one of the most attractive areas in the biopharma industry today.

Nice little article for the backdrop of potential partnerships for MSB:

https://www.labiotech.eu/in-depth/immunology-and-inflammation-market/?nab=0